Here, in human colon cancer cells, we observed for the first time that autophagy flux is enhanced by anlotinib treatment, as indicated by an increase in LC3 (autophagosome marker) and a decrease in P62 (autophagy substrate) (Fig. 3a, b, e). This evidence concerns the gene MAP1LC3A and colonic neoplasm.